Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS) Immunicum AB (publ; IMMU.ST) announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug…

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) combination therapy in…

We are 11 days from Chondrosarcoma Awareness Day. If you have not already done this, we are counting on you to do the following: 1. Get the Word Out. Join us in our efforts to educate the public about Chondrosarcoma, a rare bone and soft tissue…

The Chondrosarcoma Awareness Day is getting the attention from many media outlets across the globe. We are doing our best to raise awareness and support for Chondrosarcoma research and clinical trials. Please check out the links…

The Bowie, MD-based Chondrosarcoma CS Foundation, Inc. is launching an international public campaign to raise awareness and support for Chondrosarcoma research and clinical trials. They are proclaiming February 6, 2021, as Chondrosarcoma Awareness…

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year SAN DIEGO,…

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year Inhibrx, Inc….

Momentum is growing for our international public awareness campaign to support Chondrosarcoma Research and Clinical Trials. As you know Chondrosarcoma Awareness Day is dedicated to honor the legacy of Shayna Elise Kramer who passed away from this…